학술논문
294P Cell-free DNA (cfDNA) workflow for the risk definition of dose-limiting and recurrent neutropenia in patients treated with first-line endocrine therapy (ET) and cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) for metastatic breast cancer (MBC)
Document Type
Abstract
Author
Source
In Annals of Oncology September 2021 32 Supplement 5:S493-S493
Subject
Language
ISSN
0923-7534